Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system.

Autor: Eskelinen T; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. tommi.j.eskelinen@gmail.com., Veitonmäki T; Department of Urology, TAYS Cancer Center, Tampere, Finland., Kotsar A; Department of Urology, Tartu University Hospital, Tartu, Estonia., Tammela TLJ; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Urology, TAYS Cancer Center, Tampere, Finland., Pöyhönen A; Centre for Military Medicine, The Finnish Defence Forces, Helsinki, Finland., Murtola TJ; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Urology, TAYS Cancer Center, Tampere, Finland.; Department of Urology, Tartu University Hospital, Tartu, Estonia.
Jazyk: angličtina
Zdroj: Cancer causes & control : CCC [Cancer Causes Control] 2022 Feb; Vol. 33 (2), pp. 313-320. Date of Electronic Publication: 2021 Dec 18.
DOI: 10.1007/s10552-021-01527-w
Abstrakt: Purpose: We explored renal cell cancer (RCC) survival among users of antihypertensive medication as hypertension is proposed to be a risk factor for RCC and ACE-inhibitors and angiotensin receptor blockers (ARBs) have been associated with improved prognosis of RCC.
Methods: Finnish cohort of 13,873 participants with RCC diagnosed between 1995-2012 was formed from three national databases. RCC cases were identified from Finnish Cancer Registry, medication usage from national prescription database and co-morbidities from Care Registry of Healthcare. Logistic regression was used to calculate odds ratios for metastatic tumor extent at the time of diagnosis. Risk of RCC specific death after diagnosis was analyzed using Cox regression adjusted for tumor clinical characteristics.
Results: A total of 5,179 participants died of RCC during the follow-up. No risk association was found for metastatic tumor extent for any drug group. ACE-inhibitors, but no other drug group were associated with decreased risk of RCC specific death overall (HR 0.88, 95% CI 0.82-0.95) compared to non-users. In time-dependent analysis high-dose use of ACE-inhibitors (392 Defined Daily Dose (DDD)/year), HR 0.54, 95% CI 0.45-0.66) and ARBs (786.1 DDD/year, HR 0.66, 95% CI 0.50-0.87) associated with improved RCC survival. No information of TNM-classification or tobacco smoking was available.
Conclusion: ACE-inhibitors and ARBs in high dose associated with improved RCC specific survival. This may reflect overall benefit of treating hypertension with medication targeting renin-angiotensin system (RAS) system among RCC patients. Further studies are needed to explore the role of RAS in RCC.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: